tradingkey.logo

Eli Lilly and Co

LLY

738.210USD

-50.990-6.46%
收盘 04/04, 16:00美东报价延迟15分钟
699.48B总市值
66.05市盈率 TTM

Eli Lilly and Co

738.210

-50.990-6.46%
关于 Eli Lilly and Co 公司
礼来公司是一家制药公司。该公司在人类药品领域发现、开发、制造和销售产品。其糖尿病、肥胖症和其他心脏代谢产品包括 Basaglar、Humalog、Mounjaro、Trulicity 和 Zepbound。其肿瘤产品包括 Alimta、Retevmo、Tyvyt 和 Verzenio。其免疫学产品包括 Ebglyss、Olumiant、Omvoh 和 Taltz。其神经科学产品包括 Cymbalta 和 Emgality。其其他产品和疗法包括 Cialis 和 Forteo。该公司通过位于美国(包括波多黎各)以及欧洲和亚洲的工厂生产和分销其产品。该公司通过其子公司 POINT Biopharma Global Inc. 从事放射性药物的发现、开发和制造,以及临床和临床前放射性配体疗法。该公司还在开发用于治疗炎症性肠病 (IBD) 的 α4β7 整合素口服小分子抑制剂 (称为 MORF-057)。
公司简介
公司代码LLY
公司名称Eli Lilly and Co
上市日期Jul 09, 1970
成立日期1901
CEOMr. David A. (Dave) Ricks
员工数量47000
证券类型Ordinary Share
年结日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NYSE Consolidated
国家United States of America
邮编46285
电话13172762000
网址https://www.lilly.com/
公司代码LLY
上市日期Jul 09, 1970
成立日期1901
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.76K
+45.24%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.16K
+0.62%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.97K
+26.18%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
收入明细
单位: USD更新时间: 4月2日 周三
单位: USD更新时间: 4月2日 周三
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
地区USD
名称
营收
占比
U.S.
30.38B
67.44%
Europe
6.92B
15.36%
Other foreign countries
4.27B
9.48%
Japan
1.81B
4.03%
China
1.66B
3.69%
业务
地区
业务USD
名称
营收
占比
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
持股股东
股东统计
占比
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
股东类型
股东统计
占比
Investment Advisor
37.91%
Investment Advisor/Hedge Fund
25.90%
Foundation
10.22%
Research Firm
1.93%
Pension Fund
1.88%
Bank and Trust
1.79%
Insurance Company
1.43%
Sovereign Wealth Fund
1.24%
Hedge Fund
1.10%
Other
16.61%
机构持股
更新时间: 2月20日 周四
更新时间: 2月20日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q1
5515
795.05M
83.86%
+1.55M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
2023Q1
4061
801.36M
84.15%
-9.39M
2022Q4
3985
805.64M
84.79%
-7.51M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lilly Endowment, Inc.
96.02M
10.13%
-220.00K
-0.23%
Mar 03, 2025
The Vanguard Group, Inc.
73.90M
7.8%
+486.78K
+0.66%
Dec 31, 2024
PNC Investments LLC
51.08M
5.39%
-49.68K
-0.10%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
41.11M
4.34%
+29.75K
+0.07%
Dec 31, 2024
State Street Global Advisors (US)
34.31M
3.62%
+461.69K
+1.36%
Dec 31, 2024
Fidelity Management & Research Company LLC
29.35M
3.1%
-2.42M
-7.60%
Dec 31, 2024
T. Rowe Price Associates, Inc.
19.73M
2.08%
-77.25K
-0.39%
Dec 31, 2024
Capital World Investors
19.55M
2.06%
-803.44K
-3.95%
Dec 31, 2024
Geode Capital Management, L.L.C.
17.38M
1.83%
+291.88K
+1.71%
Dec 31, 2024
PRIMECAP Management Company
16.76M
1.77%
-933.85K
-5.28%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月2日 周三
更新时间: 4月2日 周三
机构名称
占比
Defiance Daily Target 2X Long LLY ETF
30.83%
iShares U.S. Pharmaceuticals ETF
25.29%
Amplify Weight Loss Drug & Treatment ETF
18.44%
Roundhill GLP-1 & Weight Loss ETF
18.11%
VanEck Pharmaceutical ETF
14.74%
Proshares Ultra Health Care
13.36%
Health Care Select Sector SPDR Fund
13.35%
iShares U.S. Healthcare ETF
13.16%
Fidelity MSCI Health Care Index ETF
11.93%
Simplify Health Care ETF
11.07%
查看更多
Defiance Daily Target 2X Long LLY ETF
占比30.83%
iShares U.S. Pharmaceuticals ETF
占比25.29%
Amplify Weight Loss Drug & Treatment ETF
占比18.44%
Roundhill GLP-1 & Weight Loss ETF
占比18.11%
VanEck Pharmaceutical ETF
占比14.74%
Proshares Ultra Health Care
占比13.36%
Health Care Select Sector SPDR Fund
占比13.35%
iShares U.S. Healthcare ETF
占比13.16%
Fidelity MSCI Health Care Index ETF
占比11.93%
Simplify Health Care ETF
占比11.07%
分红派息
近5年累计派现 18.06B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
May 01, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023
May 15, 2023
Jun 09, 2023
May 12, 2023
Dec 12, 2022
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 10, 2023
Feb 14, 2023
Oct 17, 2022
LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022
Nov 15, 2022
Dec 09, 2022
Nov 14, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
tradingkey.logo
tradingkey.logo
日内数据由路孚特(Refinitiv)提供,并受使用条款约束。历史及当前收盘数据均由路孚特提供。所有报价均以当地交易所时间为准。美股报价的实时最后成交数据仅反映通过纳斯达克报告的交易。日内数据延迟至少15分钟或遵循交易所要求。
* 参考、分析和交易策略由第三方提供商Trading Central提供,观点基于分析师的独立评估和判断,未考虑投资者的投资目标和财务状况。
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有